Evaluation of clinical events and costs associated with the addition of dapagliflozin to chronic kidney disease treatment: Cost offset analysis

Autor: Juan Francisco Navarro-González, Alberto Ortiz, Ana Cebrián Cuenca, Lluís Segú, Belén Pimentel, Unai Aranda, Blanca Lopez-Chicheri, Margarita Capel, Elisenda Pomares Mallol, Christian Caudron, Juan José García Sánchez, Roberto Alcázar Arroyo

Publikováno v: Nefrología (English Edition), Vol 44, Iss 6, Pp 857-867 (2024)

Background and objectives: Chronic kidney disease (CKD) is a serious health problem with an increasing clinical, social and economic impact in advanced stages. Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor that reduces the risk of CKD p

Externí odkaz: https://doaj.org/article/e723d232252d42eca0056cf8db3cd1b4

Epidemiology, clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain

Autor: Carlos Escobar, Unai Aranda, Beatriz Palacios, Margarita Capel, Antoni Sicras, Aram Sicras, Antonio Hormigo, Roberto Alcázar, Nicolás Manito, Manuel Botana

Publikováno v: Nefrología, Vol 41, Iss 6, Pp 670-688 (2021)

Objectives: To describe the epidemiology, clinical profile, treatments, and to determine cardiovascular and renal outcomes after two years of follow-up in a contemporary chronic kidneay disease (CKD) population in Spain. This was also analyzed among

Externí odkaz: https://doaj.org/article/0c0c2cddd7c04362bff12456f4d97a61

Risk of outcomes in a Spanish population with chronic kidney disease

Autor: Roberto Alcázar, Carlos Escobar, Beatriz Palacios, Unai Aranda, Luis Varela, Margarita Capel, Antoni Sicras, Aram Sicras, Antonio Hormigo, Nicolás Manito, Manuel Botana

Publikováno v: Clinical Kidney Journal. 15:1415-1424

Objectives To assess mortality and cardiovascular and renal outcomes among patients with chronic kidney disease (CKD) (primary objective), with a particular focus on heart failure (HF) risk following diagnosis of CKD (secondary objective) in Spain. M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2543a25983fcaa6fd095c965c5111d2
https://doi.org/10.1093/ckj/sfac066

Epidemiology, clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain

Autor: Manuel Botana, Antoni Sicras, Roberto Alcázar, Nicolás Manito, Aram Sicras, Margarita Capel, Unai Aranda, Antonio Hormigo, Beatriz Palacios, Carlos Escobar

Publikováno v: Nefrología (English Edition), Vol 41, Iss 6, Pp 670-688 (2021)
Dipòsit Digital de la UB
Universidad de Barcelona
Nefrología, Vol 41, Iss 6, Pp 670-688 (2021)

Objectives: To describe the epidemiology, clinical profile, treatments, and to determine cardiovascular and renal outcomes after two years of follow-up in a contemporary chronic kidneay disease (CKD) population in Spain. This was also analyzed among

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::544863ded70845d0819f96fb18be42d7
http://hdl.handle.net/2445/183524

Empagliflozin in combination with oral agents in young and overweight/obese Type 2 diabetes mellitus patients: A pooled analysis of three randomized trials

Autor: Arantxa García, Unai Aranda, Susanne Crowe, Irene Romera, Pedro de Pablos-Velasco, Ebrahim Naderali, Sanja Giljanovic Kis, Ramon Gomis

Publikováno v: Journal of diabetes and its complications. 30(8)

Aims: This analysis aimed to evaluate efficacy and safety of empagliflozin in combination therapy in < 65 y.o.patients, overweight/obese, and with uncontrolled T2DM. Methods: Pooled analysis from three phase-III trials, in < 65 y.o. patients, with BM

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ef6a81ebf6dcc71b59587977bb2f5b9
https://pubmed.ncbi.nlm.nih.gov/27499456